Publication Year: 2017

Identification of Oral Estrogen Receptor PROTAC® Degraders for Breast Cancer

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

Lessons in PROTAC® Design from Selective Degradation with a Promiscuous Warhead

BET protein proteolysis targeting chimera (PROTAC®) exerts potent lethal activity against mantle cell lymphoma cells

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs®) of TANK-Binding Kinase 1

An Oral Androgen Receptor PROTAC® Degrader for Prostate Cancer

An Oral Androgen Receptor PROTAC® Degrader for Prostate Cancer

IHC and flow cytometry quantifies BRD4 levels in surrogate tissues after ex-vivo and in-vivo dosing with a BRD4 degrading PROTAC®

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells